Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma

References

1. 1.↵
   1. Ostrom QT,
   2. Cioffi G,
   3. Gittleman H, et al

   . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1–100 doi:10.1093/neuonc/noz150 pmid:31675094

   CrossRefPubMed
2. 2.↵
   1. Stupp R,
   2. Hegi ME,
   3. Mason WP, et al

   ; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66 doi:10.1016/S1470-2045(09)70025-7 pmid:19269895

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Lombardi G,
   2. Pambuku A,
   3. Bellu L, et al

   . Effectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2017;111:94–102 doi:10.1016/j.critrevonc.2017.01.018 pmid:28259301

   CrossRefPubMed
4. 4.↵
   1. Wainwright DA,
   2. Chang AL,
   3. Dey M, et al

   . Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014;20:5290–301 doi:10.1158/1078-0432.CCR-14-0514 pmid:24691018

   Abstract/FREE Full Text
5. 5.↵
   1. Zeng J,
   2. See AP,
   3. Phallen J, et al

   . Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86:343–49 doi:10.1016/j.ijrobp.2012.12.025 pmid:23462419

   CrossRefPubMed
6. 6.↵
   Bristol-Myers Squibb Announces Phase 3 CheckMate-498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-498-study-did. May 9, 2019. Accessed March 30, 2020
7. 7.↵
   Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate-548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-provides-update-phase-3-opdivo-nivolumab-. September 5, 2019. Accessed March 30, 2020.
8. 8.↵
   1. Reardon DA,
   2. Brandes AA,
   3. Omuro A, et al

   . Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 randomized clinical trial. JAMA Oncol 2020;6:1003–10 doi:10.1001/jamaoncol.2020.1024 pmid:32437507

   CrossRefPubMed
9. 9.↵
   1. Reardon DA,
   2. Kaley TJ,
   3. Dietrich J, et al

   . Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: an update. J Clin Oncol 2017;35:2042 doi:10.1200/JCO.2017.35.15_suppl.2042

   CrossRef
10. 10.↵
    1. Huang RY,
    2. Wen PY

    . Response assessment in neuro-oncology criteria and clinical endpoints. Magn Reson Imaging Clin N Am 2016;24:705–18 doi:10.1016/j.mric.2016.06.003 pmid:27742111

    CrossRefPubMed
11. 11.↵
    1. Okada H,
    2. Weller M,
    3. Huang R, et al

    . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16: e534–42 doi:10.1016/S1470-2045(15)00088-1 pmid:26545842

    CrossRefPubMed
12. 12.↵
    1. Reardon DA,
    2. Omuro A,
    3. Brandes AA, et al

    . OS10.3 randomized Phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol 2017;19:iii21 doi:10.1093/neuonc/nox036.071

    CrossRef
13. 13.↵
    Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma. https://clinicaltrials.gov/ct2/show/NCT02336165. Accessed February 1, 2022
14. 14.↵
    1. Reardon DA,
    2. Kaley TJ,
    3. Dietrich J, et al

    . Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). J Clin Oncol 2019;37(15 Suppl):2032 doi:10.1200/JCO.2019.37.15_suppl.2032

    CrossRef
15. 15.↵
    1. Zwanenburg A,
    2. Leger S,
    3. Vallieres M, et al

    . Image biomarker standardisation initiative. https://arxiv.org/abs/1612.07003. December 2, 2016. Accessed February 1, 2022
16. 16.↵
    Documentation/Nightly/Modules/SwissSkullStripper. https://www.slicer.org/wiki/Documentation/Nightly/Modules/SwissSkullStripper. Accessed February 1, 2022
17. 17.↵
    1. Chang K,
    2. Zhang B,
    3. Guo X, et al

    . Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol 2016;18:1680–87 doi:10.1093/neuonc/now086 pmid:27257279

    CrossRefPubMed
18. 18.↵
    1. Vallières M,
    2. Freeman CR,
    3. Skamene SR, et al

    . A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol 2015;60:5471–96 doi:10.1088/0031-9155/60/14/5471 pmid:26119045

    CrossRefPubMed
19. 19.↵
    1. Vallieres M,
    2. Kay-Rivest E,
    3. Perrin LJ, et al

    . Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci Rep 2017;7:10117 doi:10.1038/s41598-017-10371-5 pmid:28860628

    CrossRefPubMed
20. 20.↵
    A repository to develop code for IBSI compliant radiomics applications. https://github.com/mvallieres/radiomics-develop. Accessed April 26, 2020
21. 21.↵
    1. Ishwaran H,
    2. Kogalur UB,
    3. Blackstone EH, et al

    . Random survival forests. Annals of Applied Statistics 2008;2:841–60
22. 22.↵
    scikit-survival. https://scikit-survival.readthedocs.io/en/stable/. Accessed February 1, 2022
23. 23.↵
    1. Hung H,
    2. Chiang C

    . Estimation methods for time-dependent AUC models with survival data. The Canadian Journal of Statistics 2009;38:8–26
24. 24.↵
    1. Rundo F,
    2. Spampinato C,
    3. Banna GL, et al

    . Advanced deep learning embedded motion radiomics pipeline for predicting anti-PD-1/PD-L1 immunotherapy response in the treatment of bladder cancer: preliminary results. Electronics 2019;8:1134 doi:10.3390/electronics8101134

    CrossRef
25. 25.↵
    1. Jazieh K,
    2. Khorrami M,
    3. Saad AM, et al

    . Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with chemoradiation and durvalumab. J Clin Oncol 2021;39(15 Suppl):3054–54 doi:10.1200/JCO.2021.39.15_suppl.3054

    CrossRef
26. 26.↵
    1. Sforazzini F,
    2. Salome P,
    3. Kudak A, et al

    . PD-L1-R: A MR based surrogate for PD-L1 expression in glioblastoma multiforme. J Clin Oncol 2021;39:2041 doi:10.1200/JCO.2021.39.15_suppl.2041

    CrossRef
27. 27.↵
    1. Lotan E,
    2. Jain R,
    3. Razavian N, et al

    . State of the art: machine learning applications in glioma imaging. AJR Am J Roentgenol 2019;212:26–37 doi:10.2214/AJR.18.20218 pmid:30332296

    CrossRefPubMed
28. 28.↵
    1. Sengupta A,
    2. Ramaniharan AK,
    3. Gupta RK, et al

    . Glioma grading using a machine-learning framework based on optimized features obtained from T1 perfusion MRI and volumes of tumor components. J Magn Reson Imaging 2019;50:1295–1306 doi:10.1002/jmri.26704 pmid:30895704

    CrossRefPubMed
29. 29.↵
    1. Zhang B,
    2. Chang K,
    3. Ramkissoon S, et al

    . Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol 2017;19:109–17 doi:10.1093/neuonc/now121 pmid:27353503

    CrossRefPubMed
30. 30.↵
    1. Chang K,
    2. Beers AL,
    3. Bai HX, et al

    . Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro Oncol 2019;21:1412–22 doi:10.1093/neuonc/noz106 pmid:31190077

    CrossRefPubMed
31. 31.↵
    1. Macyszyn L,
    2. Akbari H,
    3. Pisapia JM, et al

    . Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. Neuro Oncol 2016;18:417–25 doi:10.1093/neuonc/nov127 pmid:26188015

    CrossRefPubMed
32. 32.↵
    1. Sanghani P,
    2. Ang BT,
    3. King NK, et al

    . Overall survival prediction in glioblastoma multiforme patients from volumetric, shape and texture features using machine learning. Surg Oncol 2018;27:709–14 doi:10.1016/j.suronc.2018.09.002 pmid:30449497

    CrossRefPubMed
33. 33.↵
    1. Kickingereder P,
    2. Burth S,
    3. Wick A, et al

    . Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models. Radiology 2016;280:880–89 doi:10.1148/radiol.2016160845 pmid:27326665

    CrossRefPubMed
34. 34.↵
    1. Grossmann P,
    2. Narayan V,
    3. Chang K, et al

    . Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2017;19:1688–97 doi:10.1093/neuonc/nox092 pmid:28499022

    CrossRefPubMed
35. 35.↵
    1. Kickingereder P,
    2. Gotz M,
    3. Muschelli J, et al

    . Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. Clin Cancer Res 2016;22:5765–71 doi:10.1158/1078-0432.CCR-16-0702 pmid:27803067

    Abstract/FREE Full Text
36. 36.↵
    1. Wang C,
    2. Sun W,
    3. Kirkpatrick J, et al

    . Assessment of concurrent stereotactic radiosurgery and bevacizumab treatment of recurrent malignant gliomas using multi-modality MRI imaging and radiomics analysis. J Radiosurg SBRT 2018;5:171–81 pmid:29988289

    PubMed
37. 37.↵
    1. Nie D,
    2. Lu J,
    3. Zhang H, et al

    . Multi-channel 3D deep feature learning for survival time prediction of brain tumor patients using multi-modal neuroimages. Sci Rep 2019;9:1103 doi:10.1038/s41598-018-37387-9 pmid:30705340

    CrossRefPubMed
38. 38.↵
    1. Zhao J,
    2. Chen AX,
    3. Gartrell RD, et al

    . Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 2019;25:462–69 doi:10.1038/s41591-019-0349-y pmid:30742119

    CrossRefPubMed
39. 39.↵
    1. Lipson EJ,
    2. Forde PM,
    3. Hammers HJ, et al

    . Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 2015;42:587–600 doi:10.1053/j.seminoncol.2015.05.013 pmid:26320063

    CrossRefPubMed
40. 40.↵
    1. De Felice F,
    2. Pranno N,
    3. Marampon F, et al

    . Immune check-point in glioblastoma multiforme. Crit Rev Oncol Hematol 2019;138:60–69 doi:10.1016/j.critrevonc.2019.03.019 pmid:31092387

    CrossRefPubMed
41. 41.↵
    1. Burugu S,
    2. Dancsok AR,
    3. Nielsen TO

    . Emerging targets in cancer immunotherapy. Semin Cancer Biol 2018;52:39–52 doi:10.1016/j.semcancer.2017.10.001 pmid:28987965

    CrossRefPubMed